OBJECTIVE Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD. RESEARCH DESIGN AND METHODS We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 ± 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 ± 13 years; 71% female) before and 6 months after starting GLP-1RA. RESULTS We observed reduction in weight (95 ± 23 to 91 ± 22 kg; P = 0.002), BMI (33 ± 6 to 31 ± 6 kg/m2; P = 0.001), HbA1c (8.2% ± 1.4% to 7.7% ± 1.4%; P = 0.02), and fasting glucose (186 ± 64 to 166 ± 53 mg/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two cases with FPLD with longer therapy. CONCLUSIONS Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.

中文翻译：

---

胰高血糖素样肽 1 激动剂在家族性部分性脂肪营养不良患者的回顾性研究中的疗效和安全性

目的 胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 广泛用于治疗糖尿病 (DM)，但其在家族性部分脂肪营养不良 (FPLD) 中的疗效尚不清楚。在这项回顾性研究中，我们评估了 GLP-1RA 对 FPLD 患者的疗效。研究设计和方法 我们分析了 14 名 FPLD 患者（年龄 58 ± 12 岁；76.47% 女性）和 14 名 2 型 DM 患者（年龄 58 ± 13 岁；71% 女性）术前和 6 个月的数据，并以 SD 报告。开始 GLP-1RA 后。结果 我们观察到体重下降（95 ± 23 至 91 ± 22 kg；P = 0.002）、BMI（33 ± 6 至 31 ± 6 kg/m2；P = 0.001）、HbA1c（8.2% ± 1.4% 至 7.7% ± FPLD 患者的空腹血糖（1.4%；P = 0.02）和空腹血糖（186 ± 64 至 166 ± 53 mg/dL；P = 0.04）。与 DM 组相比，FPLD 组治疗后甘油三酯的变化更大（P = 0.02）。我们注意到两例 FPLD 患者因长期治疗而出现急性胰腺炎。结论 我们的研究证明了 GLP-1RA 在 FPLD 患者中的相对安全性和有效性。